DTech Liquidating

DTech Liquidating EBITDA Growth YoY

Delisted

The Year-over-Year EBITDA Growth of DTech Liquidating (DMTKQ) as of Nov 18, 2026 is 12.21 %. In the previous year, Year-over-Year EBITDA Growth was -52.67 % — a change of -123.18% (higher).

EBITDA Growth YoY

12.21 %

YoY

-123.18%

Last updated:

Year-over-Year EBITDA Growth of DTech Liquidating is 2023 12.21 % . Year-over-Year EBITDA Growth of DTech Liquidating was 2022 -52.67 % . It decreases by -123.18% higher compared to the previous year.

The DTech Liquidating EBITDA Growth YoY history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBITDA Growth YoY
Date
EBITDA Growth YoY
Jan 1, 2018
-538.71 USD
Jan 1, 2019
-789.39 USD
Jan 1, 2020
-100.40 USD
Jan 1, 2021
-119.33 USD
Jan 1, 2022
-52.67 USD
Jan 1, 2023
12.21 USD
The DTech Liquidating EBITDA Growth YoY history
YEAREBITDA Growth YoYYoY
12.21 %-123.18%
-52.67 %-55.86%
-119.33 %+18.85%
-100.40 %-87.28%
-789.39 %+46.53%
-538.71 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

DTech Liquidating Stock analysis

What does DTech Liquidating do? DermTech, Inc. develops and sells non-invasive genomics tests for skin disease diagnosis and treatment, focusing on melanoma detection. The company's primary product, the DermTech Melanoma Test (DMT), marketed as Pigmented Lesion Assay (PLA), analyzes skin samples collected via Smart Stickers to identify genomic markers linked to melanoma. Healthcare providers and dermatologists purchase these tests to assess pigmented skin lesions, addressing unmet needs in diagnosing melanoma early. The company's technology enables non-invasive early detection of higher-risk lesions, reducing unnecessary biopsies. DermTech's commercial test targets the diagnostic pathway for pigmented skin lesions, commonly known as moles, which are dark-colored patches of skin. The firm's focus on inflammatory skin diseases and aging-related skin conditions complements its melanoma detection offerings. By enhancing early melanoma detection through genomic analysis, DermTech provides a solution for clinicians managing skin cancer risks without invasive procedures. The company's products are designed to facilitate clinical assessment of skin lesions that raise melanoma concerns, streamlining the diagnostic process. DermTech's approach to non-invasive testing supports healthcare systems by improving efficiency in skin cancer management. The firm's technology specifically addresses genomic markers associated with melanoma, offering a targeted solution for high-risk lesion identification. DTech Liquidating is one of the most popular companies on Eulerpool.

Frequently Asked Questions about DTech Liquidating stock

Year-over-Year EBITDA Growth of DTech Liquidating is 12.21 % in 2023.

On Eulerpool you can find the complete historical development of Year-over-Year EBITDA Growth DTech Liquidating since 2006 – with annual values, charts, and detailed analysis.

EBITDA growth measures the percentage change in EBITDA compared to the prior year. It shows changes in operating cash earnings before capital structure effects.

To evaluate Year-over-Year EBITDA Growth's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Year-over-Year EBITDA Growth.

Year-over-Year EBITDA Growth's is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Year-over-Year EBITDA Growth's DTech Liquidating historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Growth — DTech Liquidating

All Key Metrics — DTech Liquidating